Bibliotecas PUC-SP - Busca Integrada

Patient and Healthcare Professional Perspectives from ESMO 2022 on Bladder and Kidney Cancer: A Podcast

Por Alex Filicevas, Thomas Powles
Publicado no Oncology and Therapy (2023-06-01)

The management of low-stage non-seminomatous germ cell tumors

Por Louise Lim, Thomas Powles
Publicado no Oncology Reviews (2012-10-01)

Treatment Optimization and Management of AEs with Enfortumab Vedotin + Pembrolizumab for Untreated Locally Advanced/Metastatic Urothelial Cancer: A Podcast

Por Thomas Powles, Maria Lapuente, Benjamin Garmezy
Publicado no Oncology and Therapy (2025-08-01)

Cytoreductive nephrectomy in the current treatment algorithm

Por Teele Kuusk, Bernadett Szabados, Wing Kin Liu, Thomas Powles, Axel Bex
Publicado no Therapeutic Advances in Medical Oncology (2019-09-01)

Patient needs in advanced Renal Cell Carcinoma: What are patients’ priorities and how well are we meeting them?

Por Rick Harris, Kate Oake, Robert Hawkins, Robert Jones, Thomas Powles, David Montgomery
Publicado no Patient Experience Journal (2015-11-01)

The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer

Por Thomas Powles, Siobhan McFaul, Justin Stebbing, Peter Wilson, Tim Oliver et al
Publicado no OncoTargets and Therapy (2008-09-01)

Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial

Por Darren R. Feldman, Robert Huddart, Emma Hall, Jörg Beyer, Thomas Powles
Publicado no Journal of Cancer (2011-01-01)

Role of Perioperative Immune Checkpoint Inhibitors in Muscle Invasive Bladder Cancer

Por Saachi Chhaya, Isabella Watts, Kenrick Ng, Rami Mustapha, Thomas Powles, Anand Sharma, Nikhil Vasdev
Publicado no Oncology and Therapy (2023-01-01)

Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm

Por James L. Gulley, Peter Mulders, Peter Albers, Jacques Banchereau, Michel Bolla, Klaus Pantel, Thomas Powles
Publicado no OncoImmunology (2016-04-01)

445 The relationship between immune-related adverse events (irAEs) and ctDNA status: exploratory analysis from IMvigor010

Por Thomas Powles, Sanjeev Mariathasan, Rajat Mohindra, G Scott Chandler, Corey Carter, Katrin Madjar, Bogdana I Balas, Laurent Essioux, Viraj Degaonkar
Publicado no Journal for ImmunoTherapy of Cancer (2023-11-01)

First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients

Por Christof Vulsteke, Laurens De Cocker, Alfonso Gómez de Liaño, Cristina Montesdeoca, Astrid De Meulenaere, Lieselot Croes, Danielle Delombaerde, Bernadett Szabados, Thomas Powles
Publicado no Pharmaceuticals (2023-03-01)

ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic uro...

Por Ben Fulton, Robert Jones, Thomas Powles, Simon Crabb, James Paul, Alison Birtle, Simon Chowdhury, Syed Hussain, Anna Morris, Eileen Soulis, Paula Morrison
Publicado no Trials (2020-04-01)

Criteria Used to Determine Platinum Eligibility in Patients with Metastatic Urothelial Carcinoma: Results of a Physician Survey in Five European Countries

Por Shilpa Gupta, Thomas Powles, Mairead Kearney, Laura Panattoni, Natalie Land, Thomas Flottemesch, Patrick Sullivan, Melissa Kirker, Murtuza Bharmal, Silke Guenther, Nuno Costa, Enrique Grande
Publicado no European Urology Open Science (2025-11-01)

Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer

Por Alexander L. R. Lubbock, Grant D. Stewart, Fiach C. O’Mahony, Alexander Laird, Peter Mullen, Marie O’Donnell, Thomas Powles, David J. Harrison, Ian M. Overton
Publicado no BMC Medicine (2017-06-01)

Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advance...

Por Nobuaki Matsubara, Junji Yonese, Takahiro Kojima, Haruhito Azuma, Hiroaki Matsumoto, Thomas Powles, Jonathan E. Rosenberg, Daniel P. Petrylak, Maria Matsangou, Chunzhang Wu, Mary Campbell, Mayumi Yamashiro
Publicado no Cancer Medicine (2023-02-01)

Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RAN...

Por Andrea Necchi, Hiroyuki Nishiyama, Nobuaki Matsubara, Jae-Lyun Lee, Daniel P. Petrylak, Ronald de Wit, Alexandra Drakaki, Astra M. Liepa, Huzhang Mao, Katherine Bell-McGuinn, Thomas Powles
Publicado no BMC Urology (2020-11-01)

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

Por Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George
Publicado no BMC Cancer (2021-09-01)

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

Por Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George
Publicado no BMC Cancer (2021-08-01)

The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer

Por Caitlin R. Davies, Tianyu Guo, Tianyu Guo, Edwina Burke, Elzbieta Stankiewicz, Elzbieta Stankiewicz, Lei Xu, Lei Xu, Xueying Mao, Glenda Scandura, Prabhakar Rajan, Prabhakar Rajan, Prabhakar Rajan, Prabhakar Rajan, Karen Tipples, Constantine Alifrangis, Constantine Alifrangis, Akhila Ganeshi Wimalasingham, Myria Galazi, Shanthini Crusz, Thomas Powles, Thomas Powles, Alistair Grey, Alistair Grey, Alistair Grey, Tim Oliver, Sakunthala Kudahetti, Greg Shaw, Greg Shaw, Greg Shaw, Daniel Berney, Jonathan Shamash, Yong-Jie Lu
Publicado no Frontiers in Oncology (2023-01-01)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

Por Chung-Wei Lee, Thomas Powles, Sabina Signoretti, Sumanta K Pal, Toni K Choueiri, Brian I Rini, Saby George, Robert J Motzer, Frede Donskov, Scott S Tykodi, Nizar M Tannir, Saurabh Gupta, Ruiyun Jiang
Publicado no Journal for ImmunoTherapy of Cancer (2022-12-01)